Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification
文献类型：期刊论文
| 作者 | Yu, Ruixue; Shi, Run; Chen, Jinghua; Zheng, Xinhua; Yu, Ruitao |
| 刊名 | ACS OMEGA
 |
| 出版日期 | 2025 |
| 卷号 | 10期号:18页码:19019 |
| 英文摘要 | Cirrhosis, characterized by liver fibrosis and structural remodeling, is a leading cause of liver cancer. The Fuzheng Huayu formula (FZHY) has been approved for treating liver fibrosis in China since 2002, but its effects and mechanisms on cirrhosis remain largely unknown. This study employed network pharmacology, molecular docking, and in vitro experiments to elucidate the specific mechanisms of FZHY against liver cirrhosis. First, intersecting genes between FZHY and cirrhosis were obtained from the Chinese Medicine System Pharmacology Database, the Swiss Target Prediction online platform, UniProt, GeneCards, DisGeNET, and OMIM. The STRING database was used to construct a protein-protein interaction network. Subsequently, Gene Ontology functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed, followed by molecular docking analysis to verify binding affinities between active ingredients and candidate targets. These analyses provided a theoretical basis for subsequent experimental research. Finally, we identified 117 FZHY target genes associated with cirrhosis and constructed a drug-component-target-cirrhosis-pathway network. Enrichment analysis revealed the AGE-RAGE signaling pathway in diabetic complications as a key pathway. Molecular docking showed that Isotanshinone II had the highest affinity for CHUK, IKBKB, and MAPK14. In vitro experiments demonstrated that Isotanshinone II dose-dependently reduced the mRNA expression of COL1A1 and alpha-SMA, as well as the protein levels of MAPK p38, IKK beta, and NF-kappa B p65 in LX-2 cells. These results revealed the underlying mechanism by which Isotanshinone II in FZHY inhibited LX-2 cell activation and collagen production through suppression of the MAPK/NF-kappa B signaling pathway. These findings support Isotanshinone II as a promising compound for cirrhosis targeting the MAPK/NF-kappa B pathway. Further research is warranted to explore the bioavailability of Isotanshinone II and to optimize its structure for clinical applications. |
| 源URL | [http://210.75.249.4/handle/363003/62462]  |
| 专题 | 西北高原生物研究所_中国科学院西北高原生物研究所 |
| 推荐引用方式 GB/T 7714 | Yu, Ruixue,Shi, Run,Chen, Jinghua,et al. Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification[J]. ACS OMEGA,2025,10(18):19019. |
| APA | Yu, Ruixue,Shi, Run,Chen, Jinghua,Zheng, Xinhua,&Yu, Ruitao.(2025).Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification.ACS OMEGA,10(18),19019. |
| MLA | Yu, Ruixue,et al."Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification".ACS OMEGA 10.18(2025):19019. |
入库方式： OAI收割
来源：西北高原生物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。